Cargando…
The comparative effects of oral Chinese patent medicines in non-proliferative diabetic retinopathy: A Bayesian network meta-analysis of randomized controlled trials
BACKGROUND: Non-proliferative diabetic retinopathy (NPDR), a common diabetic complication with high morbidity, is featured by impaired visual function and fundus lesions. It has been reported that oral Chinese patent medicines (OCPMs) may improve visual acuity and fund signs. However, the best possi...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10106679/ https://www.ncbi.nlm.nih.gov/pubmed/37077355 http://dx.doi.org/10.3389/fendo.2023.1144290 |
_version_ | 1785026456996282368 |
---|---|
author | Liu, Ziqiang Chen, Yunru Jie, Chuanhong Wang, Jianwei Deng, Yu Hou, Xiaoyu Li, Yuanyuan Cai, Wenjing |
author_facet | Liu, Ziqiang Chen, Yunru Jie, Chuanhong Wang, Jianwei Deng, Yu Hou, Xiaoyu Li, Yuanyuan Cai, Wenjing |
author_sort | Liu, Ziqiang |
collection | PubMed |
description | BACKGROUND: Non-proliferative diabetic retinopathy (NPDR), a common diabetic complication with high morbidity, is featured by impaired visual function and fundus lesions. It has been reported that oral Chinese patent medicines (OCPMs) may improve visual acuity and fund signs. However, the best possible OCPMs for NPDR remain questionable and merit further investigation. METHODS: From inception to October 20, 2022, seven databases were searched for eligible randomized controlled trials (RCTs). The outcomes were clinical effective rate, visual acuity, visual field gray value, microaneurysm volume, hemorrhage area, macular thickness, and adverse events rate. The revised Cochrane risk-of-bias tool (ROB 2) was used to assess the quality of the included studies. Network meta-analysis was performed using R 4.1.3 and STATA 15.0 software. RESULTS: We included 42 RCTs with 4,858 patients (5,978 eyes). The Compound Danshen Dripping Pill (CDDP) combined with calcium dobesilate (CD) had the most improvement in clinical efficacy rate (SUCRA, 88.58%). The Compound Xueshuantong Capsule (CXC) combined with CD may be the best intervention (SUCRA, 98.51%) for the improvement of visual acuity. CDDP alone may be the most effective treatment option (SUCRA, 91.83%) for improving visual field gray value. The Hexuemingmu Tablet (HXMMT) and Shuangdan Mingmu Capsule (SDMMC) combined with CD may be the most effective treatment for reducing microaneurysm volume and hemorrhage area (SUCRA, 94.48%, and 86.24%), respectively. Referring to reducing macular thickness, CXC combined with CD ranked first (SUCRA, 86.23%). Moreover, all OCPMs did not cause serious adverse reactions. CONCLUSION: OCPMs are effective and safe for NPDR. CDDP alone, and combined with CD, may be the most effective in improving visual field gray value and clinical efficacy rate, respectively; CXC combined with CD may be the best in enhancing BCVA and reducing macular thickness; HXMMT and SDMMC combined with CD, maybe the most effective regarding microaneurysm volume and hemorrhage area, respectively. However, the reporting of methodology in the primary study is poor, potential biases may exist when synthesizing evidence and interpreting the results. The current findings need to be confirmed by more large-sample, double-blind, multi-center RCTs of rigorous design and robust methods in the future. SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/prospero/, identifier CRD42022367867. |
format | Online Article Text |
id | pubmed-10106679 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-101066792023-04-18 The comparative effects of oral Chinese patent medicines in non-proliferative diabetic retinopathy: A Bayesian network meta-analysis of randomized controlled trials Liu, Ziqiang Chen, Yunru Jie, Chuanhong Wang, Jianwei Deng, Yu Hou, Xiaoyu Li, Yuanyuan Cai, Wenjing Front Endocrinol (Lausanne) Endocrinology BACKGROUND: Non-proliferative diabetic retinopathy (NPDR), a common diabetic complication with high morbidity, is featured by impaired visual function and fundus lesions. It has been reported that oral Chinese patent medicines (OCPMs) may improve visual acuity and fund signs. However, the best possible OCPMs for NPDR remain questionable and merit further investigation. METHODS: From inception to October 20, 2022, seven databases were searched for eligible randomized controlled trials (RCTs). The outcomes were clinical effective rate, visual acuity, visual field gray value, microaneurysm volume, hemorrhage area, macular thickness, and adverse events rate. The revised Cochrane risk-of-bias tool (ROB 2) was used to assess the quality of the included studies. Network meta-analysis was performed using R 4.1.3 and STATA 15.0 software. RESULTS: We included 42 RCTs with 4,858 patients (5,978 eyes). The Compound Danshen Dripping Pill (CDDP) combined with calcium dobesilate (CD) had the most improvement in clinical efficacy rate (SUCRA, 88.58%). The Compound Xueshuantong Capsule (CXC) combined with CD may be the best intervention (SUCRA, 98.51%) for the improvement of visual acuity. CDDP alone may be the most effective treatment option (SUCRA, 91.83%) for improving visual field gray value. The Hexuemingmu Tablet (HXMMT) and Shuangdan Mingmu Capsule (SDMMC) combined with CD may be the most effective treatment for reducing microaneurysm volume and hemorrhage area (SUCRA, 94.48%, and 86.24%), respectively. Referring to reducing macular thickness, CXC combined with CD ranked first (SUCRA, 86.23%). Moreover, all OCPMs did not cause serious adverse reactions. CONCLUSION: OCPMs are effective and safe for NPDR. CDDP alone, and combined with CD, may be the most effective in improving visual field gray value and clinical efficacy rate, respectively; CXC combined with CD may be the best in enhancing BCVA and reducing macular thickness; HXMMT and SDMMC combined with CD, maybe the most effective regarding microaneurysm volume and hemorrhage area, respectively. However, the reporting of methodology in the primary study is poor, potential biases may exist when synthesizing evidence and interpreting the results. The current findings need to be confirmed by more large-sample, double-blind, multi-center RCTs of rigorous design and robust methods in the future. SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/prospero/, identifier CRD42022367867. Frontiers Media S.A. 2023-04-03 /pmc/articles/PMC10106679/ /pubmed/37077355 http://dx.doi.org/10.3389/fendo.2023.1144290 Text en Copyright © 2023 Liu, Chen, Jie, Wang, Deng, Hou, Li and Cai https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Endocrinology Liu, Ziqiang Chen, Yunru Jie, Chuanhong Wang, Jianwei Deng, Yu Hou, Xiaoyu Li, Yuanyuan Cai, Wenjing The comparative effects of oral Chinese patent medicines in non-proliferative diabetic retinopathy: A Bayesian network meta-analysis of randomized controlled trials |
title | The comparative effects of oral Chinese patent medicines in non-proliferative diabetic retinopathy: A Bayesian network meta-analysis of randomized controlled trials |
title_full | The comparative effects of oral Chinese patent medicines in non-proliferative diabetic retinopathy: A Bayesian network meta-analysis of randomized controlled trials |
title_fullStr | The comparative effects of oral Chinese patent medicines in non-proliferative diabetic retinopathy: A Bayesian network meta-analysis of randomized controlled trials |
title_full_unstemmed | The comparative effects of oral Chinese patent medicines in non-proliferative diabetic retinopathy: A Bayesian network meta-analysis of randomized controlled trials |
title_short | The comparative effects of oral Chinese patent medicines in non-proliferative diabetic retinopathy: A Bayesian network meta-analysis of randomized controlled trials |
title_sort | comparative effects of oral chinese patent medicines in non-proliferative diabetic retinopathy: a bayesian network meta-analysis of randomized controlled trials |
topic | Endocrinology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10106679/ https://www.ncbi.nlm.nih.gov/pubmed/37077355 http://dx.doi.org/10.3389/fendo.2023.1144290 |
work_keys_str_mv | AT liuziqiang thecomparativeeffectsoforalchinesepatentmedicinesinnonproliferativediabeticretinopathyabayesiannetworkmetaanalysisofrandomizedcontrolledtrials AT chenyunru thecomparativeeffectsoforalchinesepatentmedicinesinnonproliferativediabeticretinopathyabayesiannetworkmetaanalysisofrandomizedcontrolledtrials AT jiechuanhong thecomparativeeffectsoforalchinesepatentmedicinesinnonproliferativediabeticretinopathyabayesiannetworkmetaanalysisofrandomizedcontrolledtrials AT wangjianwei thecomparativeeffectsoforalchinesepatentmedicinesinnonproliferativediabeticretinopathyabayesiannetworkmetaanalysisofrandomizedcontrolledtrials AT dengyu thecomparativeeffectsoforalchinesepatentmedicinesinnonproliferativediabeticretinopathyabayesiannetworkmetaanalysisofrandomizedcontrolledtrials AT houxiaoyu thecomparativeeffectsoforalchinesepatentmedicinesinnonproliferativediabeticretinopathyabayesiannetworkmetaanalysisofrandomizedcontrolledtrials AT liyuanyuan thecomparativeeffectsoforalchinesepatentmedicinesinnonproliferativediabeticretinopathyabayesiannetworkmetaanalysisofrandomizedcontrolledtrials AT caiwenjing thecomparativeeffectsoforalchinesepatentmedicinesinnonproliferativediabeticretinopathyabayesiannetworkmetaanalysisofrandomizedcontrolledtrials AT liuziqiang comparativeeffectsoforalchinesepatentmedicinesinnonproliferativediabeticretinopathyabayesiannetworkmetaanalysisofrandomizedcontrolledtrials AT chenyunru comparativeeffectsoforalchinesepatentmedicinesinnonproliferativediabeticretinopathyabayesiannetworkmetaanalysisofrandomizedcontrolledtrials AT jiechuanhong comparativeeffectsoforalchinesepatentmedicinesinnonproliferativediabeticretinopathyabayesiannetworkmetaanalysisofrandomizedcontrolledtrials AT wangjianwei comparativeeffectsoforalchinesepatentmedicinesinnonproliferativediabeticretinopathyabayesiannetworkmetaanalysisofrandomizedcontrolledtrials AT dengyu comparativeeffectsoforalchinesepatentmedicinesinnonproliferativediabeticretinopathyabayesiannetworkmetaanalysisofrandomizedcontrolledtrials AT houxiaoyu comparativeeffectsoforalchinesepatentmedicinesinnonproliferativediabeticretinopathyabayesiannetworkmetaanalysisofrandomizedcontrolledtrials AT liyuanyuan comparativeeffectsoforalchinesepatentmedicinesinnonproliferativediabeticretinopathyabayesiannetworkmetaanalysisofrandomizedcontrolledtrials AT caiwenjing comparativeeffectsoforalchinesepatentmedicinesinnonproliferativediabeticretinopathyabayesiannetworkmetaanalysisofrandomizedcontrolledtrials |